FY2026 EPS Estimates for AbbVie Cut by Erste Group Bank

AbbVie Inc. (NYSE:ABBV) – Stock analysts at Erste Group Bank cut their FY2026 EPS estimates for shares of AbbVie in a report released on Thursday, June 25th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $14.23 per share for the year, down from their previous estimate of $14.26. The consensus estimate for AbbVie’s current full-year earnings is $14.28 per share.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the previous year, the firm posted $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis.

A number of other equities analysts have also recently issued reports on the company. Piper Sandler reissued an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Morgan Stanley lifted their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Trading Up 0.2%

NYSE ABBV opened at $253.86 on Tuesday. The stock’s 50 day moving average is $216.06 and its two-hundred day moving average is $219.38. The company has a market capitalization of $448.52 billion, a price-to-earnings ratio of 125.06, a PEG ratio of 0.77 and a beta of 0.32. AbbVie has a 1-year low of $181.75 and a 1-year high of $255.99.

Institutional Investors Weigh In On AbbVie

A number of large investors have recently bought and sold shares of ABBV. Hamilton Wealth LLC raised its holdings in shares of AbbVie by 0.4% in the first quarter. Hamilton Wealth LLC now owns 22,320 shares of the company’s stock valued at $4,854,000 after buying an additional 96 shares during the last quarter. LFG Wealth Partners LLC grew its holdings in AbbVie by 11.4% during the 1st quarter. LFG Wealth Partners LLC now owns 6,903 shares of the company’s stock worth $1,501,000 after acquiring an additional 705 shares during the last quarter. FAS Wealth Partners Inc. increased its position in AbbVie by 3.6% in the 1st quarter. FAS Wealth Partners Inc. now owns 30,629 shares of the company’s stock valued at $6,661,000 after acquiring an additional 1,064 shares in the last quarter. Pine Valley Investments Ltd Liability Co increased its position in AbbVie by 2.3% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 75,560 shares of the company’s stock valued at $16,434,000 after acquiring an additional 1,727 shares in the last quarter. Finally, Evansbrook LLC raised its stake in shares of AbbVie by 1.4% in the first quarter. Evansbrook LLC now owns 3,531 shares of the company’s stock worth $768,000 after acquiring an additional 49 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma, with the study meeting its primary endpoint and showing a meaningful improvement in progression-free survival. Article Title
• Positive Sentiment: The European Medicines Agency’s CHMP issued positive opinions for Rinvoq (upadacitinib) in severe alopecia areata and non-segmental vitiligo, improving the odds of new label expansions in Europe. Article Title Article Title
• Positive Sentiment: AbbVie also announced another research milestone in its neurology collaboration with Nxera Pharma, signaling continued progress in partnered pipeline development. Article Title
• Neutral Sentiment: AbbVie remains near its 52-week high, and recent commentary notes the stock has already had a strong run, which may encourage some investors to question valuation even as the news flow stays upbeat. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.